The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025
Write the words of this act the way you think they should read. Solon shows your change as a redline against the published text and pins it to that exact text, so it can never be applied to wording you did not see.
Change 1
23 Insertion of new regulation A32
In Part 5, before regulation 32 (notification of adverse events) insert— Record keeping A32. (1) A sponsor shall keep detailed records of all serious adverse events and serious adverse reactions, including suspected unexpected serious adverse reactions, which occur during the course of a clinical trial— (a) in the United Kingdom; (b) conducted outside of the United Kingdom where— (i) the sponsor of both the trial in the United Kingdom and the trial outside of the United Kingdom is the same or, where the sponsor is a company, in the same group, and (ii) the investigational medicinal product being tested or used in the trial conducted outside of the United Kingdom is the same as the investigational medicinal product being tested or used in the clinical trial mentioned in sub-paragraph (a). (2) A sponsor shall evaluate the events and reactions mentioned in paragraph (1), with a view to— (a) minimising and preventing any risk presented by the use of the investigational medicinal product to which those events and reactions relate; and (b) taking appropriate measures as soon as reasonably practicable to investigate the risks presented and implement actions for minimising and preventing those risks. (3) For purposes of paragraph (1)(b)(i), “group” has the same meaning as in Part 15 of the Companies Act 2006 (see section 474(1) of that Act). .
23 Insertion of new regulation A32
In Part 5, before regulation 32 (notification of adverse events) insert— Record keeping A32. (1) A sponsor shall keep detailed records of all serious adverse events and serious adverse reactions, including suspected unexpected serious adverse reactions, which occur during the course of a clinical trial— (a) in the United Kingdom; (b) conducted outside of the United Kingdom where— (i) the sponsor of both the trial in the United Kingdom and the trial outside of the United Kingdom is the same or, where the sponsor is a company, in the same group, and (ii) the investigational medicinal product being tested or used in the trial conducted outside of the United Kingdom is the same as the investigational medicinal product being tested or used in the clinical trial mentioned in sub-paragraph (a). (2) A sponsor shall evaluate the events and reactions mentioned in paragraph (1), with a view to— (a) minimising and preventing any risk presented by the use of the investigational medicinal product to which those events and reactions relate; and (b) taking appropriate measures as soon as reasonably practicable to investigate the risks presented and implement actions for minimising and preventing those risks. (3) For purposes of paragraph (1)(b)(i), “group” has the same meaning as in Part 15 of the Companies Act 2006 (see section 474(1) of that Act). .
One line that says what changes, such as "Halve the dog tax".
Who it helps, what it costs, what it fixes. It is what persuades people to support it.
How this law is officially changed
Solon does not know this law's official route yet. The proposal is recorded all the same, and the route appears here once its source is added.
A proposal here is not law. Support on Solon is evidence that people want the change; the official route says what it takes to make it law.
Sign in to file your proposal. What you have written stays on this page.
Sign in to file itThink it through
Ask what your change would do, who would gain and who would bear a cost, and where something like it is already law. The assistant reads your draft as it stands, cites the law and the studies it finds, and takes no side. What you file stays yours.